Tenet (THC) Q3 2026 Earnings Call Transcript

Tenet Healthcare (THC) reported Q3 2026 revenue of $5.631B (+6.5% YoY) and adjusted EPS of $6.64 (+79.5% YoY). Adjusted EBITDA was $1.355B, with growth in ambulatory and hospital segments. The company raised FY2026 EBITDA guidance to $5.05B-$5.20B. Risks include an 18% decline in exchange admissions and Medicaid work requirements. Tenet issued $2B in senior unsecured notes and repurchased $1.615B in shares YTD.

Original reporting
Published Oct 29, 2026, 7:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tenet (THC) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$THCBullishHigh
01

Why it matters

The earnings beat and raised guidance are likely to drive short-term buying interest, though sector-specific challenges remain.

02

Market read

First-report earnings with multi‑billion dollar figures; material for traders and investors.

03

What to watch

Potential Medicaid work requirement impacts and 18% drop in exchange admissions could affect future earnings.

Relevance 9/10Novelty 9/10Timing: after-hours today

Background

Tenet Healthcare held its Q3 2026 earnings call, providing detailed financial results and forward guidance.

Company-level read

Ticker impact

$THCBullishHigh confidence
Context

Q3 2026 earnings released with $5.631B revenue, $6.64 adjusted EPS and raised FY 2026 adjusted EBITDA guidance.

Expected impact

likely modest upside as market prices in strong earnings and higher guidance

Evidence & confidence

Revenue and EPS beat expectations; FY 2026 EBITDA outlook increased, supporting a bullish reaction.

Market effects

Healthcare sector may benefit from Tenet's strong earnings and growth outlook.

U.S. equity markets could see a modest lift from the results.

Moderate, as Tenet is a large U.S. health services provider.

Counterpoint

Valuation may be stretched; headwinds from exchange admission declines could temper upside.

Key entities

  • Tenet Healthcare Corporation

    U.S.-listed health services operator reporting Q3 2026 results.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$THCHighAI 8/10

Mizuho raises Tenet Healthcare stock price target on strong results

Mizuho increased its price target for Tenet Healthcare (NYSE:THC) to $305 from $290, citing strong quarterly results and raised 2026 EBITDA estimates. The stock trades near its 52-week high after a 49% six-month surge. Tenet reported Q3 2026 EPS of $6.64, beating estimates, and raised its full-year EBITDA outlook. Guggenheim maintained a Buy rating with a slightly lowered target of $306.

$THCMed

Tenet Healthcare Q3 Earnings Call Highlights

Tenet Healthcare (THC) reported Q3 earnings, with hospital segment showing 3.2% growth in admissions and 11% adjusted EBITDA increase. Revenue per admission rose 0.2% YoY. Exchange admissions and revenues declined 18%. Conifer transition activities contributed $147M, with $450M expected in 2026. Tenet generated $1.1B in adjusted free cash flow and repurchased 970K shares.